This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
Ventricular assist devices (VADs) are essential for the management of patients with terminal heart failure or cardiomyopathy, awaiting heart transplantation or myocardial recovery. [1] [2] [3] [4] In 1992, with the introduction of miniaturized pumps for clinical use, the Berlin Heart (BH)
device became the first pulsatile VAD available for small children. 5, 6 Mechanical assistance in pediatrics has considerably evolved over a decade, providing excellent results, even for small children. 7 However, device and/or systemic thrombosis and hemorrhagic events remain the major causes of mortality and morbidity with complication rates (mainly neurologic) ranging from 20% to 60%.
2,7-11
The hemostatic changes associated with BH implantation are complex and require a challenging antithrombotic treatment. 11 Thus, an antithrombotic protocol combining anticoagulant and antiplatelet molecules is recommended. 5 Unfractionated heparin (UFH) is started soon after VAD implantation and is relayed by vitamin K antagonists or low-molecular-weight heparin once the patient's condition is fully stabilized. Within 2 to 10 days after VAD implantation, platelet inhibitors (dipyridamole or clopidogrel and aspirin) are introduced. The bitherapy is continued until the VAD is removed.
Determining hemostatic function in these patients is essential, but standard coagulation tests performed in plasma are not designed to evaluate global hemostatic function. Thus, BH's guidelines recommend using whole blood thromboelastography (TEG) and (TEG)-platelet mapping-(PM) to monitor anticoagulation and platelet inhibition in children with a BH. 5, 12, 13 TEG-PM is designed to specifically evaluate platelet inhibition secondary to antiplatelet therapy. Although this assay has been shown to correlate with light transmission aggregometry (LTA) and to have a predictive value of bleeding risks in patients undergoing percutaneous coronary intervention 14, 15 , some concerns with the design of TEG-PM assay have been recently raised. 16, 17 The aim of this retrospective analysis was to evaluate the TEG-PM assay to monitor antiplatelet therapy in children implanted with a BH.
PATIENTS AND METHODS

Patients and healthy volunteers
This retrospective study was approved by the ethical committee (N° from nine healthy volunteers after they had given their written informed consent and after it had been verified that they had no increased bleeding tendency and had not taken medication that could decrease platelet function.
Hemostasis monitoring
Blood from patients and healthy volunteers was collected in
Vacutainer tubes (BD Vacutainer System, Paymouth, UK) containing 0.109 mol L −1 sodium citrate or 15 U mL −1 heparin. The blood was drawn from the patients' arterial line following the recommendations of avoiding heparin contamination and sample dilution 19 or from the antecubital vein of healthy volunteers. To avoid platelet activation, blood specimens were transported to the laboratory by hand delivery (the pneumatic tube system was never used). 20, 21 Blood was analysed within 30 minutes after sampling.
Conventional tests
Coagulation tests (fibrinogen, anti-Xa activity, international normalized ratio (INR), antithrombin) were run according to standardized procedures on ACLTop (Werfen, Bedford, MA, USA).
TEG-PM
This technique was performed according to the manufacturer's instructions using the platelet-mapping kit (Haemonetics, Braintree, MA, USA). 22 For the standard TEG reaction, kaolin-treated citrated blood (360 μL) was transferred into a prewarmed cup containing heparinase and calcium chloride (20 μL) to measure thrombin-induced plateletfibrin clot-strength. Under these conditions, maximum amplitude (MA)
is dependent on fibrin and platelet contributions (MA thrombin ).
To eliminate the thrombin effect on platelet activation, heparinized blood (340 μL) is used and activated by reptilase in the presence of factor XIIIa (activator F) (10 μL), enabling the strength of the fibrin clot (MA fibrin ) to be specifically measured. The addition of platelet agonists 
Essentials
• Thromboelastography (TEG)-platelet mapping (PM) assay is used for antiplatelet-drug monitoring.
• The TEG-PM was evaluated for dypiridamole and aspirin monitoring in 4 BH-implanted children.
• Some TEG-PM tracings were atypical leading to wrong results.
• The TEG-PM has to be improved for antiplatelet-drug monitoring during ventricular assistance. −2 , no dose change is required; otherwise the dose must be adjusted as described in Table 1 . The aspirin dose must be adjusted to the percentage of platelet inhibition in the presence of AA: when inhibition is 70-95%, no dose change is required; otherwise the dose must be adjusted (Table 1) .
Light transmission aggregometry (LTA)
Platelet-rich plasma (PRP) and autologous platelet-poor plasma (PPP)
were obtained by centrifugations of citrated blood as recommended. 23 A photometric method on an 8-channel aggregometer (PAP-8E, Bio/ Data Corporation, Horsham, PA, USA) was used.
Platelet-rich plasma was incubated 2 minutes at 37°C and was then stirred at 122 g for 2 minutes before adding saline, ADP or AA In the last version of the BH's guidelines, when ADP-induced platelet aggregation is <50%, no dose change of dipyridamole is required;
when AA-induced platelet aggregation is <30%, no dose change of aspirin is required.
TEG-PM in healthy volunteers
TEG-PM assay was also performed in healthy volunteers using activa- 
RESULTS
Characteristics of patients
Demographic and clinical patients' characteristics are presented in Table 2 . Six patients were affected by dilated cardiomyopathy with end-stage heart failure and were assisted with a bi-VAD; one patient had myocarditis-induced dilated cardiomyopathy and was supported by a left VAD. The median duration of the support was 54 6-107 days.
Among patients with bi-VAD, 4 were successfully transplanted and 2 died. The patient assisted by a left BH was successfully explanted. T A B L E 1 Antiplatelet therapymonitoring with TEG-PM according to the Berlin Heart manufacturer's plateletinhibition protocol
Anticoagulation and platelet inhibition after BH implantation
Conventional tests were monitored at least daily (not shown). UFH was started 24-48 hours after BH implantation. The heparin dose was adjusted to achieve a target anti-Xa range of 0.35-0.5 IU mL −1
. For 6 patients, heparin was maintained during the whole assistance period.
Antithrombin was monitored daily and human antithrombin (Aclotine) administration was adjusted to achieve a target value above 70%.
The combined administration of heparin and antithrombin resulted in consistent therapeutic anticoagulation for all patients. No significant bleeding event was observed. Vitamin K antagonist (warfarin) was used in only one patient (patient 3) with an initial dose of 0.2 mg kg
after 40 days of assistance; the dose was adjusted to maintain the INR between 2.7 and 3.5. Patients who were without bleeding and hemodynamically stable (patients 3, 5, 6, and 7) received dual antiplatelet therapy (Table 3) . Aspirin was given between 6 and 9 days postimplantation when TEG-PM platelet inhibition with AA decreased below 70% according to BH's guidelines. On the contrary, dipyridamole was started between 5 and 47 days postimplantation to limit the risk of thrombosis, although the 6 dynes cm −2 threshold for G ADP indicated in BH's guidelines was reached for none of these patients.
Platelet inhibition monitoring
In the 4 patients receiving antiplatelet therapy (Table 3) , TEG-PM was repeated every 2 days during the first week and then twice weekly.
The number of TEG-PM determinations was 15 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] per patient.
Surprisingly, the correlation between MA fibrin and fibrinogen level was weak (r=.17; non significant, n=47). Moreover, in 2 patients (patients 3 and 7), PM tracings were atypical. Indeed, MA fibrin (red tracing, Figure 1 ) never stabilized, generating an atypical tracing ( Figure 1A) compared to control ( Figure 1B ). This anomaly was also observed for Dx, x days postimplantation. N/A, none applicable; LTA, light; TEG-PM, Thromboelastography-Platelet-Mapping; n, number.
a After the first observation, MA fibrin (maximum amplitude) was obtained with eptifibatide. ) was needed to achieve the desired 70% inhibition. However, AA platelet inhibition was very unstable during the following days (day 15 to day 55). Dipyridamole was introduced later than aspirin because, until day 9 postimplantation, the G ADP value remained stable, fluctuating between 2.2 and 3 dynes cm The monitoring of children receiving dual antiplatelet therapy was also done with LTA for the last 2 patients (6 and 7, Table 2 ). For patient 7, because of abnormal tracing in the classic conditions, MA fibrin with eptifibatide was taken into account for the comparison with LTA.
Overall, 15 (6 for patient 6 plus 9 for patient 7) LTA and TEG-PM were performed in parallel. LTA and TEG-PM inhibition results are shown in Table 3 . The concordance between both methods was 60% for AA (9/15) but only 27% for ADP (4/15) . In all cases of discordant results for ADP, TEG-PM showed platelet inhibition (G ADP 3. 
TEG-PM in healthy volunteers
To ). Indeed, an interindividual variability in ADP-induced platelet aggregation was previously reported, suggesting that 2 μmol L −1 ADP could be insufficient to reach full platelet activation in some subjects. 24 We thus compared the effect of ADP 
DISCUSSION
This retrospective analysis underlines the difficulties of monitoring antiplatelet therapy with TEG-PM in children implanted with pediatric
BH.
An antithrombotic protocol including platelet inhibitors is essential during mechanical circulatory support to prevent thromboembolic complications. 5, 25 Anticoagulant monitoring is relatively well-standardized, albeit sometimes more difficult in children than in adults. 26 In contrast, antiplatelet-drug monitoring remains an issue.
In general, bridged patients have suppressed platelet and coagulation functions during the acute phase after device implantation, with more frequent bleeding. This first phase is usually followed by a hypercoagulable phase during which anticoagulation and platelet inhibitors are required. These complex and clinically unpredictable hemostatic changes explain why BH recommends using the TEG-PM assay, which is presented as a convenient tool to provide an analogous profile of platelet function over time that can accurately monitor platelet antagonists in whole blood. 14,27,28 BH provides algorithms specifying the dipyridamole and aspirin dose changes according to G ADP and the percentage of platelet inhibition in the presence of AA, respectively.
However, no correlative studies on TEG-PM results and patient outcomes have been reported. Moreover, some publications highlighted the weaknesses of TEG-PM. 16, 22, 29, 30 Four out of the 7 patients implanted with BH in our series were lesser extent with AA TEG-PM. 17 In our study, using a higher ADP concentration, MA ADP increased for 3 out of 4 healthy volunteers.
These results are explained by the interindividual variability in ADPinduced platelet aggregation, as previously shown in a study on 98 healthy volunteers, among whom 2 phenotypic groups of subjects with high or low responsiveness to 2 μmol L −1 ADP could be identified. 24 However, the percentage of ADP platelet inhibition, also decreasing, remains high in healthy subjects free of antiplatelet therapy when 10 μmol L −1 ADP was used.
Our study has several limitations. The implantation of BH in children, although steadily increasing, is still rare and our study is limited by its small sample size and heterogeneity of patients. Moreover, healthy volunteers were not run in parallel of patients, and blood collection was not standardized between patients and healthy volunteers.
Thus, no comparison is allowed between patients and volunteers, but this was not the aim of this study.
Results of TEG-PM in healthy volunteers improved our understanding of patients' results by showing that spontaneous platelet activation involving ADP occurs in heparinized blood samples. This compromises TEG-PM's ability to specifically reflect platelet inhibition secondary to antiplatelet therapy with ADP inhibitors. Our conclusion is consistent with a study on 40 healthy volunteers and volunteers taking daily antiplatelet therapy that compared 5 platelet-function tests, and concluded that TEG-PM is the least suited to monitor the effects of antiplatelet agents. 30 Unfortunately, due to the necessary blood volume, such a study comparing different platelet-function test is not possible in pediatrics. 
CONCLUSION
